Allogene Therapeutics To Present Phase 1 Data On ALLO-316 For Advanced CD70 Positive Renal Cell Carcinoma At IKCS And SITC Meetings; FDA Grants RMAT Designation For Potential Single-Infusion AlloCAR T Treatment
Allogene Therapeutics To Present Phase 1 Data On ALLO-316 For Advanced CD70 Positive Renal Cell Carcinoma At IKCS And SITC Meetings; FDA Grants RMAT Designation For Potential Single-Infusion AlloCAR T Treatment
allogene therapeutics将在IKCS和海丰国际会议上发布ALLO-316用于爱文思控股CD70阳性肾细胞癌的1期数据;FDA授予RMAt标志潜在单次注射AlloCAR t治疗
Allogene Therapeutics To Present Phase 1 Data On ALLO-316 For Advanced CD70 Positive Renal Cell Carcinoma At IKCS And SITC Meetings; FDA Grants RMAT Designation For Potential Single-Infusion AlloCAR T Treatment
allogene therapeutics将在IKCS和海丰国际会议上发布ALLO-316用于爱文思控股CD70阳性肾细胞癌的1期数据;FDA授予RMAt标志潜在单次注射AlloCAR t治疗